Takeda insider files Form 144 for $287K ADS transaction

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 disclosing a proposed sale of 18,622 American Depositary Shares (ADSs) with an aggregate market value of $287,151.24. The shares—acquired through vested restricted stock units on 1 July 2025—represent less than 0.02% of the outstanding 123,490,548 ADSs. The transaction is slated for approximately 9 July 2025 on the NYSE and will be executed through Interactive Brokers LLC. No other insider sales have been reported in the past three months.

Insights

Financial Analyst

TL;DR Small insider sale (18,622 ADSs, $287K) is routine and immaterial to TAK’s capital structure or valuation.

This Form 144 indicates an upcoming disposition of a modest number of Takeda ADSs obtained via equity compensation. At <0.02% of shares outstanding and under $0.3 million in value, the filing has negligible balance-sheet or market impact. Such activity is common for executives monetising vested awards and, by itself, does not signal a change in the company’s fundamentals or outlook. Investors should view the disclosure as compliance-driven rather than a directional indicator.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	18622	287151.24	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			49912	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Takeda (TAK) ADSs are being sold under this Form 144?

The filing covers 18,622 ADSs.

What is the aggregate market value of the proposed TAK share sale?

The shares are valued at $287,151.24 in total.

When is the planned sale date for the Takeda ADSs?

The approximate sale date is 9 July 2025.

What is the source of the securities being sold?

They derive from restricted stock unit awards that vested on 1 July 2025.

How does the sale size compare to Takeda’s total ADSs outstanding?

The 18,622 ADSs represent less than 0.02% of the 123,490,548 ADSs outstanding.

Which broker will handle the transaction?

The sale will be executed through Interactive Brokers LLC.

Have there been other insider sales by this filer in the past three months?

No. The filing states “Nothing to Report” for prior 3-month sales.